Magenta sets up Dianthus merger in quick, three-month about-face after ending trial due to patient death
Magenta Therapeutics will give its spot on Nasdaq to privately-held Dianthus Therapeutics after a patient death spurred an end to Magenta’s clinical work and an exit for most of the company’s employees.
After the patient death was reported in late-January, Magenta followed up a week later saying it would go through a review of alternatives, including a merger or other transaction. The company had set out to develop an alternative pre-conditioning regimen for stem cell transplantations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.